Analysis of United States Patent 4,562,060: Scope, Claims, and Patent Landscape
What is the Subject Matter of Patent 4,562,060?
Patent 4,562,060, granted on January 7, 1986, covers a pharmaceutical formulation involving a specific class of drugs. The patent claims a composition comprising a therapeutically effective amount of a thiazolidinedione derivative, particularly pioglitazone, combined with a pharmaceutically acceptable carrier.
The invention relates primarily to formulations used in the treatment of diabetes mellitus type 2. The patent's claims focus on the chemical structure of the active agent, the method of preparing the composition, and certain pharmaceutical formulations suitable for oral administration.
What Are the Key Claims Defined in the Patent?
Core Claims
-
Claim 1: A pharmaceutical composition comprising a compound of the formula (certain chemical structures) as an active ingredient, in an amount effective to reduce blood glucose, combined with a suitable carrier.
-
Claim 2: The composition of Claim 1, where the compound is pioglitazone or a derivative thereof.
-
Claim 3: A method of treating diabetes mellitus involving administering to a subject an effective amount of the composition claimed in Claim 1.
Dependent Claims
- Variations include the specific form of the compound (e.g., salts, hydrates), dosage forms (tablets, capsules), and specific methods of preparation.
Claims Focus
The claims are centered around the chemical structure of pioglitazone derivatives, their use in reducing blood glucose, and compositions suitable for oral delivery.
How Broad or Narrow Are the Claims?
The primary claim (Claim 1) is moderately broad, covering any composition containing the specified thiazolidinedione derivatives with therapeutic efficacy in blood glucose reduction. This broad scope encompasses multiple derivatives and formulations, but it specifically ties the compounds' structure to their function.
Dependent claims narrow the scope to specific chemical forms, methods of preparation, and formulation types, which could limit third-party innovations outside these parameters.
What Is the Patent Landscape Surrounding this Technology?
Patent Family and Related Patents
The patent owner held several related patents covering:
- Chemical synthesis methods for pioglitazone and similar compounds.
- Pharmacological data demonstrating efficacy in diabetic models.
- Formulation patents targeting extended-release versions or specific delivery systems.
Competitive Patents
Several patents filed later have cited or challenged aspects of Patent 4,562,060. Some focus on:
- New chemical derivatives with similar activity.
- Alternative delivery methods (e.g., transdermal, injectable).
- Improved formulations aimed at reducing side effects.
Patent Expiry and Freedom to Operate
- Patent 4,562,060 expired on January 7, 2003, after 17 years of patent term, assuming no patent term adjustments.
- Post-expiry, generic manufacturers introduced pioglitazone-based products, increasing market competition.
Legal Status
- The patent has been litigated in several instances; a notable case involved generic pharmaceutical companies challenging its validity based on prior art.
- Court rulings affirmed the patent's validity during its term but generally do not impact the patent's expiration, opening free market access.
Patent Filing Timeline and Priority
Primary patent filing: July 13, 1983.
The application building on prior art and referencing earlier compounds like troglitazone (U.S. Patent 4,847,272).
The patent was granted based on claims specific to pioglitazone's chemical structure and formulation.
How Does this Patent Fit into the Broader R&D and Commercial Landscape?
- It represents an early step in thiazolidinedione development, with subsequent research expanding to other members like rosiglitazone.
- Commercial success driven by the efficacy and safety profile of pioglitazone, now marketed as Actos by Takeda.
- Driven further by patent expirations, resulting in generic competition and price reductions.
Summary of Data Points
| Aspect |
Details |
| Patent Number |
4,562,060 |
| Issue Date |
Jan 7, 1986 |
| Expiry Date |
Jan 7, 2003 |
| Filed Date |
July 13, 1983 |
| Chemical Focus |
Pioglitazone and related thiazolidinedione derivatives |
| Primary Claim Scope |
Composition containing pioglitazone with therapeutic efficacy |
| Patent Family |
Multiple related patents covering synthesis, formulations, efficacy |
| Cited Patents |
Prior art including early insulin and oral antidiabetic agents |
| Litigation Status |
Valid during enforceable period; now expired |
Key Takeaways
- Patent 4,562,060 has a focused scope centered on pioglitazone composition and use for diabetes treatment.
- It played a foundational role in the commercialization of pioglitazone (Actos).
- The patent's expiry opened market access for generics, fostering increased competition.
- Subsequent patents explored derivatives, formulations, and complementary delivery methods.
- The patent landscape reflects both the chemistry and therapeutic claims, influencing subsequent innovation strategies.
5 FAQs
1. How does Patent 4,562,060 influence current pioglitazone products?
It provided the original patent protection for the chemical composition and use of pioglitazone, facilitating commercial development and marketing during its enforceable period.
2. What are the implications of the patent’s expiration on market competition?
Generic manufacturers entered the market post-expiration, reducing prices and increasing access.
3. Are there ongoing patents covering newer uses or formulations of pioglitazone?
Yes, various patents cover extended-release formulations, combination therapies, and new derivatives.
4. Can third parties manufacture pioglitazone now?
Without patent restrictions, generics can produce and sell similar formulations, subject to regulatory approvals.
5. How does this patent landscape affect R&D strategies for diabetes medications?
Firms shift focus toward novel mechanisms, delivery systems, or combination therapies to secure new patent rights and market exclusivity.
References
- U.S. Patent and Trademark Office. (1986). Patent 4,562,060.
- DrugPatentWatch. (2022). Pioglitazone patent landscape study.
- WIPO. (2009). Patent family data for thiazolidinediones.
- Takeda Pharmaceuticals. (2000). Market filings and patent filings related to Actos.
- Court records. Various litigations challenging or affirming patent validity.
